Sign In
Buy BRTX
$0.339
-0.0150 (-4.23%)
At Close: Jun 03, 2026
BioRestorative Announces Updated Time for February 27th Webcasted Conference Call to Discuss Clinical Pipeline Update
08:15pm, Wednesday, 26'th Feb 2025
MELVILLE, N.Y., Feb. 26, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a clinical stage regenerative medicine innova
BioRestorative Receives FDA Fast Track Designation for BRTX-100 Chronic Lumbar Disc Disease Program
08:30am, Thursday, 20'th Feb 2025
– Underscores high unmet need for a therapeutic alternative to opioids and surgical interventions – – Reflects positive preliminary Phase 2 Safety and Efficacy data reported to date – – May
BioRestorative Therapies Announces Notice of Allowance of Key New Patent Protecting ThermoStem® Metabolic Disease Program
06:45am, Thursday, 05'th Dec 2024
– Covers cGMP manufacturing processes – – Expected to provide protection until April 29, 2040 – MELVILLE, N.Y., Dec. 05, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. (BRTX) Q3 2024 Earnings Call Transcript
07:53pm, Wednesday, 13'th Nov 2024
BioRestorative Therapies, Inc. (NASDAQ:BRTX ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Stephen Kilmer – Investor Relations Lance Alstodt – Chairman and Ch
BioRestorative Therapies Receives Expanded Tissue License from New York State Department of Health
07:10am, Tuesday, 05'th Nov 2024
– Allows for the processing of allogeneic (non-autologous) donor tissue material, including stem cells, for medical research –
BioRestorative Therapies to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
04:15pm, Thursday, 03'rd Oct 2024
MELVILLE, N.Y., Oct. 03, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a regenerative medicine innovator focused on
MELVILLE, N.Y., Sept. 19, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a clinical stage regenerative medicine innova
BioRestorative Therapies, Inc. (BRTX) Q2 2024 Earnings Call Transcript
11:26pm, Tuesday, 13'th Aug 2024
Start Time: 16:30 January 1, 0000 5:03 PM ET BioRestorative Therapies, Inc. (NASDAQ:BRTX ) Q2 2024 Earnings Conference Call August 13, 2024, 16:30 PM ET Company Participants Lance Alstodt - President,
Biorestorative Therapies, Inc. (BRTX) Reports Q2 Loss, Tops Revenue Estimates
06:56pm, Tuesday, 13'th Aug 2024
Biorestorative Therapies, Inc. (BRTX) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to loss of $0.77 per share a year ago.
BioRestorative Therapies' Chief Scientist Named New Section Editor of the Prestigious Journal of Translational Medicine
07:10am, Tuesday, 23'rd Jul 2024
- New journal section will focus on emerging and translation work in the field of regenerative medicine - MELVILLE, N.Y., July 23, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestor
BioRestorative Therapies Announces Notice of Allowance for Patent Covering Fundamental Aspect of ThermoStem® Metabolic Disease Program
07:40am, Thursday, 27'th Jun 2024
– Adds to comprehensive patent portfolio underlying novel ThermoStem ® technology platform –
BioRestorative Therapies Regains Compliance with Nasdaq Listing Rule 5250(c)(1); Reports First Quarter 2024 Financial Results
07:05am, Monday, 17'th Jun 2024
- Significant YoY improvement in operating performance - - Ends Q1-2024 with $16.4 million cash, cash equivalents, and marketable securities - MELVILLE, N.Y., June 17, 2024 (GLOBE NEWSWIRE) -- BioRest
Why Is BioRestorative Therapeutics (BRTX) Stock Up 42% Today?
11:10am, Thursday, 13'th Jun 2024
BioRestorative Therapeutics (NASDAQ: BRTX ) stock is taking off on Thursday following news that the medical company is in negotiations with an undisclosed commercial-stage regenerative medicine compan
BioRestorative Therapies in Substantive Discussions for Potential License Agreement for ThermoStem® Metabolic Disease Program
07:00am, Thursday, 13'th Jun 2024
- Brown adipose derived stem cells with brown adipogenic potential would represent a new modality for the treatment of obesity and related metabolic disorders –
Biorestorative Therapies, Inc. (BRTX) Reports Q1 Loss, Tops Revenue Estimates
06:50pm, Tuesday, 11'th Jun 2024
Biorestorative Therapies, Inc. (BRTX) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to loss of $1.53 per share a year ago.
